Page 1

Table of Contents ( Mark One ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 . OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware For the transition period from Commission file number 001-38898 APPLIED to THERAPEUTICS Applied Therapeutics , Inc. ( Exact name of registrant as specified in its charter ) ( State or Other Jurisdiction of Incorporation or Organization ) 545 Fifth Avenue , Suite 1400 , New York , NY ( Address of Principal Executive Offices ) Title of each class 81-3405262 ( I.R.S. Employer Identification No. ) Registrant's telephone number , including area code ( 212 ) -220-9226 Securities registered pursuant to Section 12 ( b ) of the Act : Common Stock $ 0.0001 par value Trading Symbol ( s ) APLT 10017 ( Zip Code ) Name of each exchange on which registered The Nasdaq Global Market Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes No ☑ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes No ☑ Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( $ 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes No Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , " " accelerated filer , ” “ smaller reporting company ” and “ emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer Accelerated filer Non - accelerated filer ☑ Smaller reporting company ☑ Emerging growth company ☑ If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes No ☑ Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . The approximate aggregate market value of voting stock held by non - affiliates of the registrant , based upon the last sale price of the registrant's common stock on the last business day of the registrant's most recently completed second fiscal quarter , June 30 , 2020 , as reported on the Nasdaq Global Market , was approximately $ 659,242,807 . This calculation excludes approximately 8,704,807 shares held by directors , executive officers and 10 % or greater shareholders of the registrant . Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant . As of March 17 , 2021 , the total number of shares outstanding of the registrant's Common Stock was 26,009,399 shares , net of treasury shares . Documents Incorporated by Reference : Portions of the registrant's definitive proxy statement for the registrant's 2021 annual meeting , to be filed within 120 days after the close of the registrant's fiscal year , are incorporated by reference into Part III of this Annual Report on Form 10 - K .